MDxHealth Licenses Epigenetic Technology to oncgnostics
News Jan 14, 2015
MDxHealth SA has granted a limited worldwide license for its patented methylation specific PCR (MSP) technology to oncgnostics GmbH in Jena, Germany.
"oncgnostics is pleased to obtain a license to MDxHealth's proprietary epigenetic technology for use in our cervical cancer diagnostics programs. This technology allows for the accurate and sensitive assessment of DNA methylation markers included in our first test GynTect®, which is intended for the early detection of cervical neoplasias that may progress to cancer," said Dr. Alfred Hansel, Chief Executive Officer of oncgnostics.
Under the agreement, MDxHealth grants oncgnostics a limited, non-transferable, non-exclusive, worldwide license for its patented methylation specific PCR (MSP) technology for diagnostic applications in cervical cancer. In return, MDxHealth will receive upfront and milestone payments, and royalties on net sales. oncgnostics is one of the few diagnostic companies with a strong focus on applications in gynecological cancers, including cervical cancer.
"We are pleased to work with oncgnostics, an up-and-coming player in women's health. With three successful epigenetic products based on MDxHealth's proprietary MSP technology and biomarkers on the market; our lead product ConfirmMDx® for Prostate Cancer, PredictMDx® for Glioblastoma (MGMT) and our licensee Exact Sciences' Cologuard® test for colorectal cancer screening, DNA methylation is a proven diagnostic tool for cancer detection," said Dr. Jan Groen, CEO of MDxHealth. "We are excited about oncgnostics epigenetic GynTect® test, which will aid in the diagnosis and treatment of women with cervical cancer."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019
16th International Conference on Structural Biology
Mar 11 - Mar 12, 2019